ArticleInfectious agents and cancer2025
Kaposi sarcoma incidence and mortality trends and disparities in the United States.
Article in Infectious agents and cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundKaposi sarcoma (KS) is an angioproliferative tumor caused by human herpesvirus 8 and is an AIDS-defining illness. Combination antiretroviral therapy (ART) was introduced in the United States in 1996, after which U.S. KS incidence declined and survival improved; however, persistent racial and sex disparities remain. Our aim was to characterize 1999-2020 trends in KS incidence and mortality in the United States overall, and by race and sex, and to quantify changes in disparities over time.
methodsWe extracted KS case and death counts from the CDC WONDER database (ICD-10 codes B21.0, C46). Age-adjusted incidence rates (AAIR) and mortality rates (AAMR) per 100,000 were calculated by year, race, and sex. Temporal trends were evaluated using the Mann-Kendall test (Kendall's τ), and between-group differences by t-test (α = 0.05).
resultsFrom 1999 to 2020, 27,886 KS cases and 4,380 deaths occurred. Overall AAIR was 0.99 in men versus 0.10 in women, and AAMR 0.16 versus 0.01 (both p < 0.001). Black men experienced the highest AAIR (2.23) and AAMR (0.40), significantly exceeding White men (0.79 and 0.13; p < 0.001). Incidence declined in both sexes (men: -46.7%, τ = -0.920; women: -58.9%, τ = -0.848; both p < 0.001). Mortality declined in men (-66.4%, τ = -0.581; p < 0.001). Among women, AAMR levels were very low throughout (mean ≈ 0.01 per 100,000); the end-to-end change from 1999 to 2020 was + 28.6%, yet the Mann-Kendall test did not identify a monotonic trend (τ = - 0.303; p = 0.060), reflecting early declines followed by year-to-year fluctuation around a low baseline.
conclusionAlthough KS incidence and mortality have declined markedly since 1999, Black men remain disproportionately affected. Focused public health efforts and enhanced access to HIV care are essential to close these gaps. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.